You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

BELLUS Health Inc unchanged

BELLUS Health Inc closed unchanged Tuesday sitting at $1.05. Over the last five days, shares have lost 6.25% and are down 25.00% for the last year to date. This security has outperformed the S&P TSX by 18.14% during the last year.

About

BELLUS Health Inc. (BELLUS Health) is engaged in developing drugs for rare diseases, starting with conditions that affect the kidneys. The Company’s lead program is KIACTA,

Continue reading

a drug candidate in a Phase III Confirmatory Study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. BELLUS Health is involved in a research-stage project for the treatment of AL amyloidosis, a rare disease in which amyloid protein builds up and causes dysfunction in various parts of the body, including the kidneys, heart, liver and peripheral nerves. It is developing Shigamab, an antibody treatment for hemolytic uremic syndrome caused by Shiga toxin-producing E. coli (sHUS). Shigamab is a monoclonal antibody therapy being developed for the treatment of sHUS. It principally affects the kidneys and often leads to acute dialysis, and in certain cases chronic kidney disease and death, primarily in children.

Restrictions

All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. Thomson Reuters is not liable for any errors or delays in Thomson Reuters content, or for any actions taken in reliance on such content. ‘Thomson Reuters’ and the Thomson Reuters logo are trademarks of Thomson Reuters and its affiliated companies.